CDKN1B and neoplasm: In particular, the minor allele T confers risk for neuroblastoma development and correlates with decreased mRNA levels of CDKN1B. We also show that high CDKN1B mRNA expression levels correlate with favourable tumour stages and show association with a better clinical outcome.